Dr. Fanger is currently co-founder and CEO of Rise Therapeutics. His extensive career has been in the biotechnology industry, developing novel therapeutics, establishing drug development alliances, and leading M&A activities. He serves as a director on the board of Virtici and previously for OncoImmune, that was acquired by Merck for $420 million in 2020. In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Dr. Fanger helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation. Dr. Fanger received his MBA from Seattle University, PhD from Dartmouth Medical School, and his BS from Denison University.